Cefuroxime
Cefuroxime, sold under the brand name Zinacef among others, is a second-generation cephalosporin[1] antibiotic used to treat and prevent a number of bacterial infections.[2] These include pneumonia, meningitis, otitis media, sepsis, urinary tract infections, and Lyme disease.[3] See also Cefuroxime. Cefuroxime is active against many bacteria including susceptible strains of Staphylococci and Streptococci, as well as a range of gram negative organisms.[4] As with the other cephalosporins, it is susceptible to beta-lactamase, although as a second-generation variety, it is less so. Hence, it may have greater activity against Haemophilus influenzae, Neisseria gonorrhoeae, and Lyme disease. Unlike other second-generation cephalosporins, cefuroxime can cross the blood–brain barrier.[5] 3zg9.
|
| ||||||||||
ReferencesReferences
- ↑ Katzung B (2018). Basic & Clinical Pharmacology. McGraw Hill. p. 803.
- ↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 518. ISBN 9780857113382.
- ↑ "Cefuroxime Sodium Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 22 March 2019.
- ↑ "Appendix 5 – Antibiotic overview". Wellington ICU Drug Manual. Retrieved 7 April 2023
- ↑ Root RK, Waldvogel F, Corey L, Stamm WE (1999). Clinical Infectious Diseases: A Practical Approach. Oxford University Press. p. 259. ISBN 9780195081039